Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
1.
Thyroid ; 32(6): 714-724, 2022 06.
Article in English | MEDLINE | ID: mdl-35297659

ABSTRACT

Background: Thyroid hormone has a differential action on healthy and ischemic heart. Triiodothyronine (T3) administration improved postischemic cardiac function while it limited apoptosis in experimentally induced ischemia. Thus, the present study investigated the potential effects of acute liothyronine (LT3) treatment in patients with anterior myocardial infarction. Methods: This study is a pilot, randomized, double-blind, placebo-controlled trial (ThyRepair study). We randomized 52 patients and analyzed data from 37 patients (n = 16 placebo and n = 21 LT3), per prespecified per protocol analysis. We excluded three patients who had died of cardiovascular causes (one in placebo and two in LT3 arm), four with small infarct size below a pre-specified threshold (in the placebo arm), and the rest, who lacked follow-up data. LT3 treatment started after stenting as an intravenous (i.v.) bolus injection of 0.8 µg/kg of LT3 followed by a constant infusion of 0.113 µg/kg/h i.v. for 48 hours. All patients had cardiac magnetic resonance (CMR) at hospital discharge and 6 months follow-up. The primary end point was CMR left ventricular (LV) ejection fraction (LVEF) and secondary endpoints were LV volumes, infarct volume (IV), and safety. Results: The CMR LVEF% at 6 months was 53.6 ± 9.5 for the LT3-treated group and 48.6 ± 11 for placebo, p = 0.15. Acute LT3 treatment resulted in a significantly lower LV end-diastolic volume index (92.2 ± 16.8 mL/m2 vs. 107.5 ± 22.2, p = 0.022) and LV systolic volume index (47.5 ± 13.9 mL/m2 vs. 61.3 ± 21.7, p = 0.024) at hospital discharge, but not at 6 months. There was no statistically significant difference in CMR IV at hospital discharge between the groups (p = 0.24). CMR IV tended to be lower in the LT3-treated group at 6 months (18.7 ± 9.5 vs. 25.9 ± 11.7, in placebo, p = 0.05). Serious, life-threatening events related to LT3 treatment were not observed. A tendency for an increased incidence of atrial fibrillation (AF) was found in the LT3 group during the first 48 hours (19% for T3 group vs. 5% for placebo, p = 0.13). Conclusion: This pilot randomized, placebo-controlled trial study suggests potential favorable effects (acute cardiac dilatation and 6-month IV) as well as potential concerns regarding a higher risk of AF after LT3 administration early after myocardial infarction, which should be tested in a larger scale study.


Subject(s)
Myocardial Infarction , Triiodothyronine , Angioplasty , Double-Blind Method , Humans , Myocardial Infarction/drug therapy , Pilot Projects , Treatment Outcome , Triiodothyronine/therapeutic use
10.
Hellenic J Cardiol ; 52(5): 462-5, 2011.
Article in English | MEDLINE | ID: mdl-21940296

ABSTRACT

A large intracardiac mass is a rare condition and one with an extremely high risk of haemodynamic and embolic complications. Urgent surgical excision is the treatment of choice, and the histological examination reveals the exact nature of the mass, usually a myxoma or a thrombus. We present the case of an 80-year-old woman, with a history of atrial fibrillation, who was admitted because of a seriously impaired level of consciousness, and fever. A large cerebral infarct and a urinary tract infarction were diagnosed. On the transthoracic echocardiogram a giant, free-floating mass was detected in the left atrium, transiently obstructing the mitral valve orifice. Based on the features of the mass and patient's history, it was considered more likely to be a thrombus rather than a tumour. Given the patient's extremely unfavourable neurological status, cardiac surgery was considered to be contraindicated and the patient was administered unfractionated heparin intravenously. Unfortunately, after a few hours the patient suffered a cardiac arrest and died.


Subject(s)
Atrial Fibrillation/complications , Heart Diseases/complications , Thrombosis/complications , Aged, 80 and over , Fatal Outcome , Female , Heart Atria , Heart Diseases/pathology , Humans , Thrombosis/pathology
11.
Hellenic J Cardiol ; 52(2): 177-81, 2011.
Article in English | MEDLINE | ID: mdl-21478131

ABSTRACT

We present the case of a 42-year-old man with mitral valve prolapse (MVP) and infective endocarditis. He was referred to our hospital by his family physician for the evaluation of a cardiac murmur. A detailed medical history revealed that he had been feeling fatigue with occasional episodes of slight fever during the last two months. Echocardiography revealed MVP with a sizeable vegetation and severe mitral insufficiency. Serial blood cultures were positive for Streptococcus viridans, highly penicillin susceptible. He was put on appropriate antimicrobial therapy, but both the vegetation and the concomitant mitral insufficiency persisted after otherwise successful medical therapy. Thus, the patient underwent surgical vegetectomy with mitral valve repair. He had an uneventful postoperative course and remains free of disease at the 12-month follow up. Our case report reinforces the value of early diagnosis in the presence of a high clinical suspicion of MVP endocarditis. An extended clinical workup, including serial detailed echocardiography studies, is mandatory in such a patient. Medical treatment of infective endocarditis in the setting of MVP is often successful. However, cardiac surgical intervention plays an important role in the treatment of intracardiac complications. Mitral valve repair in the context of a healed and stable infective endocarditis is the treatment of choice.


Subject(s)
Endocarditis, Bacterial/surgery , Mitral Valve Prolapse/surgery , Streptococcal Infections/therapy , Viridans Streptococci , Adult , Endocarditis, Bacterial/complications , Endocarditis, Bacterial/diagnosis , Humans , Male , Mitral Valve Prolapse/diagnosis , Mitral Valve Prolapse/microbiology , Streptococcal Infections/diagnosis
12.
Hellenic J Cardiol ; 52(1): 75-8, 2011.
Article in English | MEDLINE | ID: mdl-21292610

ABSTRACT

Coronary artery fistulas are rare anomalies of the coronary arteries that may sometimes be totally asymptomatic and can be found incidentally during coronary arteriography later in adult life. We report the case of a 75-year-old man with such a fistula and describe our diagnostic approach. In addition, we review the literature on the etiology, epidemiology, the diagnostic modalities and treatment of coronary fistulas.


Subject(s)
Coronary Vessel Anomalies/diagnosis , Vascular Fistula/diagnosis , Aged , Coronary Angiography , Coronary Vessel Anomalies/diagnostic imaging , Coronary Vessel Anomalies/therapy , Humans , Incidental Findings , Magnetic Resonance Imaging , Male , Vascular Fistula/diagnostic imaging , Vascular Fistula/therapy
14.
Int J Cardiol ; 146(3): e53-5, 2011 Feb 03.
Article in English | MEDLINE | ID: mdl-19185363

ABSTRACT

Dual left anterior descending artery (LAD) is a rare coronary artery anomaly. Dual but normally originated LAD has been usually reported to have no clinical significance. In this case report, we present a case of a middle age year old male with atypical anginal symptoms in whom coronary arteriography showed dual LAD with anomalous origin of one branch from the right coronary artery.


Subject(s)
Coronary Vessel Anomalies/diagnostic imaging , Coronary Angiography , Humans , Male , Middle Aged
15.
Int J Cardiol ; 142(1): 87-91, 2010 Jun 25.
Article in English | MEDLINE | ID: mdl-19200613

ABSTRACT

INTRODUCTION: Congestive heart failure (HF) is characterised by increased proinflammatory stimulation and impaired endothelial function. Statin treatment exerts a beneficial effect on endothelial function and inflammatory process in patients with atherosclerosis. However, its effect in patients with HF is not well studied. Therefore, in the present study we compared the effect of short-term treatment with rosuvastatin or ezetimibe on endothelial function in patients with HF. METHODS: In this double-blind, placebo controlled, cross-over trial, 22 patients with HF were randomised to receive ezetimibe 20 mg/d or rosuvastatin 10 mg/d for 4 weeks, with 4 weeks wash-out period between the two interventions. Endothelial function was evaluated by flow mediated dilation (FMD) in the brachial artery at the beginning and at the end of each treatment period. RESULTS: There was no change in the baseline brachial diameter after treatment with either ezetimibe (p=NS) or rosuvastatin (p=NS). However, there was a significant improvement of FMD in the rosuvastatin group (p<0.05) but not in the ezetimibe group (p=NS). The changes in lipid levels were similar between groups (p=NS). The change in FMD was not significantly correlated with the decrease of serum LDL in either the ezetimibe or rosuvastatin treated groups. CONCLUSIONS: Rosuvastatin improves endothelial function in patients with congestive heart failure, by mechanisms independent of lipid-lowering. On the contrary, lipid-lowering treatment achieved by ezetimibe is unable to affect endothelial function in these patients. These findings indicate a direct beneficial effect of statins in patients with congestive heart failure, further to lipid-lowering.


Subject(s)
Azetidines/therapeutic use , Endothelium, Vascular/physiology , Fluorobenzenes/therapeutic use , Heart Failure/drug therapy , Heart Failure/physiopathology , Lipids/blood , Pyrimidines/therapeutic use , Sulfonamides/therapeutic use , Azetidines/pharmacology , Cross-Over Studies , Double-Blind Method , Endothelium, Vascular/drug effects , Ezetimibe , Female , Fluorobenzenes/pharmacology , Heart Failure/blood , Humans , Male , Middle Aged , Pyrimidines/pharmacology , Rosuvastatin Calcium , Sulfonamides/pharmacology , Vasodilation/drug effects , Vasodilation/physiology
17.
Hellenic J Cardiol ; 50(2): 155-9, 2009.
Article in English | MEDLINE | ID: mdl-19329420

ABSTRACT

Recurrent syncope is a common clinical problem. Patients with recurrent syncope frequently undergo extensive investigations that consume significant health care resources. Nevertheless, in a large percentage of patients syncope remains unexplained. The implantable loop recorder is a recognized diagnostic tool that can provide a definitive diagnosis and thus permit specific treatment. We present the case of a woman with recurrent syncope who was referred to our cardiology department for further investigation. Her last episode had led to a fall that caused her serious injuries. The initial routine workup was negative for cardiac, neurologic or metabolic causes of syncope. The implantable loop recorder revealed an arrhythmic origin for the recurrent syncope. The patient was managed appropriately with pacemaker implantation and has remained asymptomatic for one year.


Subject(s)
Diagnostic Techniques, Cardiovascular/instrumentation , Heart Rate/physiology , Syncope/diagnosis , Aged , Diagnosis, Differential , Electrocardiography, Ambulatory/methods , Electrodes, Implanted , Equipment Design , Female , Follow-Up Studies , Humans , Recurrence , Syncope/physiopathology
18.
Eur J Cardiovasc Prev Rehabil ; 16(1): 85-90, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19188809

ABSTRACT

AIMS: To compare the treatment and outcomes of myocardial infarction patients in hospitals with and without catheterization laboratory. METHODS AND RESULTS: The Hellenic Infarction Observation Study was a countrywide registry of acute myocardial infarction, conducted during 2005-2006. The registry enrolled 1840 patients with myocardial infarction from 31 hospitals with a proportional representation of all types of hospitals and of all geographical areas. Out of these patients, 645 (35%) were admitted in 11 hospitals with and 1195 (65%) in 20 hospitals without catheterization laboratory. Patients admitted in hospitals with catheterization laboratory in comparison with patients admitted in hospitals without were younger (66+/-14 vs. 68+/-13, P<0.004) with less diabetes (27 vs. 33%, P<0.001), but without other baseline differences (female 27 vs. 25%, prior myocardial infarction 20 vs. 17%, Killip class>1 22 vs. 23%). Reperfusion rates for ST-segment elevation myocardial infarction were 67% (43% lytic, 24% primary percutaneous coronary interventions) versus 56% (55% lytic, 1% percutaneous coronary interventions; P<0.01). In-hospital outcomes in hospitals with versus in hospitals without laboratory were: mortality 6.5 versus 8.3% (NS), stroke 2.2 versus 1.1% (NS), major bleeding 1.1 versus 0.6% (NS), and heart failure 11 versus 16% (P<0.01). In multivariate regression analysis, being admitted in a hospital without catheterization laboratory was not an independent predictor of increased in-hospital mortality (odds ratio=1.18, 95% confidence interval: 0.72-1.93, P=0.505). CONCLUSION: Although the majority of acute myocardial infarction patients was admitted in hospitals without catheterization laboratory, these patients do not have a survival disadvantage, provided they are treated with lytic therapy, medical secondary prevention drugs, and eventual revascularization according to current guidelines.


Subject(s)
Cardiac Catheterization , Health Facilities/statistics & numerical data , Hospitalization , Myocardial Infarction/therapy , Outcome Assessment, Health Care , Adrenergic beta-Antagonists/therapeutic use , Aged , Angina Pectoris/epidemiology , Angioplasty, Balloon, Coronary , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Anticoagulants/therapeutic use , Drug Utilization , Female , Greece/epidemiology , Heart Failure/epidemiology , Heparin/therapeutic use , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Male , Myocardial Infarction/epidemiology , Myocardial Reperfusion , Platelet Aggregation Inhibitors/therapeutic use , Recurrence , Registries , Shock/epidemiology , Stroke/epidemiology
19.
Cases J ; 2(1): 84, 2009 Jan 23.
Article in English | MEDLINE | ID: mdl-19166609

ABSTRACT

BACKGROUND: Cardiac involvement in patients with polymyositis is well-documented and includes myocarditis, coronary arteritis, pericarditis, valvular dysfunction and arrhythmias. CASE REPORT: There are only few reports of acute myocarditis in patients with polymyositis and, although it usually follows a chronic, mild course, it may occasionally become life-threatening. We describe the case of a 36-year-old young woman suffering from polymyositis who presented with clinical signs and symptoms mimicking an ST Elevation Acute Coronary Syndrome. The atypical features of the pain, the young age of the woman, the lack of significant cardiovascular risk factors and the medical history of an autoimmune disease, led us to reconsider our initial diagnosis towards the presence of focal myocarditis. CONCLUSION: We describe our diagnostic approach and comment on our speculations and decisions about the treatment of such a life threatening event.

20.
Int J Cardiol ; 134(3): e129-31, 2009 May 29.
Article in English | MEDLINE | ID: mdl-18554734

ABSTRACT

A 58-year-old man with no history of cardiac diseases or cardiovascular risk factors was stung by honeybees. Soon after, he gradually developed signs of an allergic reaction followed by severe retrosternal pain. Electrocardiographic, echocardiographic evidence and positive biochemical markers were consistent with an acute anterolateral myocardial infarction. Coronary arteriography showed a left anterior descending artery thrombotic lesion. This is a case of Kounis syndrome, which is the concurrence of acute coronary syndromes with conditions associated with mast cell activation including allergic or hypersensitivity reactions as well as anaphylactic or anaphylactoid insults. The clinical implications and pathophysiology of this dangerous association are discussed.


Subject(s)
Acute Coronary Syndrome/diagnosis , Bees , Insect Bites and Stings/complications , Myocardial Infarction/diagnosis , Acute Coronary Syndrome/etiology , Animals , Humans , Male , Middle Aged , Myocardial Infarction/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...